According to The Insight Partners' research, the South & Central America Infectious Disease In vitro Diagnostics Market was valued at US$ 2,092.8 Million in 2024 and is expected to reach US$ 2,676.5 Million by 2031, registering a CAGR of 3.6% from 2025 to 2031.
Government initiatives to increase awareness regarding infectious diseases and technological advancements are among the critical factors attributed to the South & Central America infectious disease in-vitro diagnostics market expansion.
Government efforts to raise awareness on infectious diseases, as well as their diagnosis, hold a major opportunity in the infectious disease in vitro diagnostics market. Initiatives focused on early detection, disease management, and strengthening the health system are fueling the demand for diagnostic products worldwide.
Public health initiatives such as immunization campaigns, school-based education programs, and community-level screenings are raising public awareness and utilization of diagnostic tests. Disease-control national programs for diseases such as tuberculosis, HIV, hepatitis, malaria, and dengue incorporate a mass screening element into the program, leading to sustained demand for centralized and point-of-care diagnostic platforms.
Governments are also backing diagnostic innovation with R&D investments, regulatory expediting, and public-private collaborations. In lower- and middle-income economies, WHO's Essential Diagnostics List (EDL) and programs such as FIND and the Global Fund are supporting high-burden disease diagnostics priority setting and funding. Additionally, greater investment in national preparedness strategies and disease surveillance, particularly after the COVID-19 pandemic, has placed infectious disease diagnosis at the forefront. These efforts not only increase testing infrastructure but also create favorable regulatory and funding conditions, setting government-led awareness campaigns as a primary opportunity for growth within the IVD market.
Partnerships with international health organizations and government subsidies help improve access to these diagnostic tools, especially in rural and underserved areas. This supportive environment attracts investments from diagnostic companies aiming to develop and distribute innovative testing solutions tailored to the needs of a specific country or region. Overall, government-driven awareness campaigns are expected to create lucrative opportunities in the infectious disease IVD market by creating sustained demand for diagnostic innovations.
On the contrary, inadequate reimbursement scenario hampers the growth of South & Central America infectious disease in-vitro diagnostics market.
South & Central America Infectious Disease In vitro Diagnostics Market Segmentation Analysis:
- By Applications, the South & Central America Infectious Disease In vitro Diagnostics Market is segmented into HIV or AIDS, Tuberculosis, Hepatitis B and C, Malaria, and Others. The Hepatitis B and C segment is projected to expand at 3.3% CAGR during 2025 - 2031.
- By End User, the South & Central America Infectious Disease In vitro Diagnostics Market is segmented into Hospitals and Clinics, Diagnostic Laboratories, Blood Bank, and Others. The Hospitals and Clinics segment is projected to expand at 3.5% CAGR during 2025 - 2031.
By country, the South & Central America Infectious Disease In vitro Diagnostics Market is categorized into Brazil, Argentina, and the Rest of South & Central America. Brazil is projected to expand at 3.7% CAGR during 2025 - 2031.
Key players operating in the Infectious Disease In vitro Diagnostics Market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Sysmex Corp, bioMerieux SA, Bio-Rad Laboratories Inc, QIAGEN NV, Bruker Corp, QuidelOrtho Corp; Becton, Dickinson and Co; and Danaher Corp, among others.
- In January 2025, Danaher Diagnostics LLC and Danaher Ventures LLC, two subsidiaries of Danaher Corporation, a global science and technology innovator, announced today that they have formed an investment partnership with Innovaccer Inc., a leading healthcare artificial intelligence (AI) company.
- In July 2022,Roche announced the launch of the Elecsys HCV Duo immunoassay in countries that accept the CE Mark. The Elecsys HCV Duo immunoassay enables a significantly earlier diagnosis of active HCV infection, making it possible to get patients appropriate care sooner to stop both the disease progression and transmission.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com